Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 29, 2024

Entinostat, Nivolumab, and Ipilimumab for Women With Advanced HER2-Negative Breast Cancer

Nature Cancer


Additional Info

Nature Cancer
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial
Nat Cancer 2024 Feb 14;[EPub Ahead of Print], ET Roussos Torres, WJ Ho, L Danilova, JA Tandurella, J Leatherman, C Rafie, C Wang, A Brufsky, P LoRusso, V Chung, Y Yuan, M Downs, A O'Connor, SM Shin, A Hernandez, EL Engle, R Piekarz, H Streicher, Z Talebi, MA Rudek, Q Zhu, RA Anders, A Cimino-Mathews, EJ Fertig, EM Jaffee, V Stearns, RM Connolly

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading